2nd World Congress on Gynecology & Obstetrics at Miami, USA

2nd World Congress on Gynecology & Obstetrics scheduled to be held in Miami, USA during September 19-20, 2019 Our two main two scientific sessions are Maternal Fetal medicine  & Midwifery explained below
Maternal Fetal Medicine :
Maternal–fetal medicine is a branch of medicine that focuses on managing health concerns of the mother and fetus prior to, during, and shortly after pregnancy.
                    
2nd World Congress on Gynecology & Obstetrics
Challenges:  Approximately one-third of women in the United States give birth via cesarean delivery. While life-saving in the right circumstances, cesarean birth also carries with it significant risks, including an increased likelihood of infection, hysterectomy, placenta implantation abnormalities in future pregnancies, and respiratory illness in infants. In a study presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting, researchers unveiled findings that suggest that induction of labor at 39 weeks of gestation among healthy, first-time mothers reduces the rate of cesarean birth as compared to expectant management among the same population.
In a study with more than 6,100 pregnant women across the country, researchers randomly assigned half of the women to an expectant management group (waiting for labor to begin on its own and intervening only if problems occur) and the other half to a group that would undergo an elective induction (inducing labor without a medical reason) at 39 weeks of gestation. Results include:
  • Lower rates of cesarean birth among the elective induction group (19%) as compared to the expectant management group (22%)
  • Lower rates of preeclampsia and gestational hypertension in the elective induction group (9%) as compared to the expectant management group (14%)
  • Lower rates of respiratory support among newborns in the induction group (3%) as compared to the expectant management group (4%)
"Safe reduction of the primary cesarean is an important strategy in improving birth outcomes, one of our Doctor who presented today's findings and is professor in obstetrics and gynecology at Northwestern University's Feinberg School of Medicine. The research presented is part of, "A Randomized Trial of Induction Versus Expectant Management," more commonly referred to as the ARRIVE Trial, which was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
SMFM's current guidelines do not recommend routine induction of labor for low-risk pregnant women at 39 weeks of gestation. "SMFM will wait to evaluate the peer-reviewed publication of the ARRIVE Trial before providing any guidance or changes to our existing recommendations," said Alfred Abuhamad, MD, the President of SMFM.
Midwifery is the health science and health profession that deals with pregnancy, childbirth, and the postpartum period (including care of the newborn), in addition to the sexual and reproductive health of women throughout their lives.
he health care system -- what the researchers call "midwifery integration" -- and birth outcomes. States with high midwifery integration, like Washington and Oregon, generally had better re

Challenges:
Midwife-friendly laws and regulations tend to coincide with lower rates of premature births, cesarean deliveries and newborn deaths, according to a new U.S.-wide "report card" that ranks all 50 states on the quality of their maternity care.

The first-of-its-kind study found a strong connection between the role of midwives in t sults, while states with the least integration, primarily in the Midwest and South, tended to do worse. The findings were published today in the journal.
"Our findings suggest that in states where families have greater access to midwifery care that is well integrated into the maternity system, mothers and babies tend to experience improved outcomes. The converse was also demonstrated; where integration of midwives is poorer, so are outcomes," said Melissa Cheyney, a licensed midwife, medical anthropologist and associate professor in Oregon State University's College of Liberal Arts and one of the study's co-authors.
As with most population health studies, the statistical association between the role of midwives and birth outcomes doesn't prove a cause-and-effect relationship. Other factors, especially race, loom larger, with African-Americans experiencing a disproportionate share of negative outcomes. However, almost 12 percent of the variation in neonatal death across the U.S. is attributable solely to how much of a part midwives play in each state's health care system.
"In communities in the U.S. that are underserved -- where the health system is often stretched thin -- this study suggests that expanding access to midwifery is a critical strategy for improving maternal and neonatal health outcomes," said Saraswathi Vedam, an associate professor in the Department of Family Practice at the University of British Columbia, who led the team of U.S. epidemiology and health policy researchers responsible for the study.
About 10 percent of U.S. births involve midwives, far behind other industrialized countries, where midwives participate in half or more of all deliveries. Each state has its own laws and regulations on midwives' credentialing, their ability to provide services at a client's home or at birth centers, their authority to prescribe medication and the degree to which they are reimbursed by Medicaid.
"A large body of cross-cultural research has actually demonstrated similar relationships between midwifery care, systems integration and improved maternity care outcomes," Cheyney said. "This study is important because it suggests that the same relationships hold true in the United States. There are significant policy implications stemming from this work."
The research team created a midwifery integration score based on 50 criteria covering those and other factors that determine midwives' availability, scope of practice and acceptance by other health care providers in each state.
Washington had the highest integration score, 61 out of a possible 100, followed by New Mexico at 59 and Oregon at 58. North Carolina had the lowest score, 17. The complete list, with links to each state's report card.
An interactive map created by the researchers reveals two clusters of higher midwifery integration -- one swath stretching from the Pacific Northwest to the Southwest, and a cluster of Northeastern states.
Vermont, Maine, Alaska and Oregon had the highest density of midwives, as measured by the number of midwives per 1,000 births. The lowest midwifery integration was in the Midwest and Deep South.
The study used higher rates of vaginal birth and breastfeeding as positive maternity care outcomes. Higher rates of caesarean birth, premature births, low birth weight and newborn deaths were indicators of poor outcomes.
The Deep South, which not only had lower integration scores, but also higher rates of African American births, had the worst rates of premature birth, low birth weight and newborn mortality. The West Coast states of California, Oregon and Washington consistently scored well on those measures.
Contact Information :
David Williams | Organizing committee  
E mail id : wcgo-2019@scientificfederation.org
Phone Number : 04068176306
Website :  https://scientificfederation.com/gynecology-2019/
Checking the heartbeat of babies in the womb is set to become more accurate and less stressful for expectant mothers thanks to research by the University of Sussex.



Dr Elizabeth Rendon-Morales has a developed a much more effective sensor to measure baby’s heartbeat without needing to visit a hospital.
It could help detect heart-related congenital disorders during pregnancy or highlight the need for medical interventions due to complications such as premature delivery or umbilical cord compression.
The new technology would also greatly benefit women experiencing high-risk pregnancy factors, such as high blood pressure, diabetes, preeclampsia and gestational high blood pressure, who require regular monitoring to ensure the wellbeing of their baby.
Dr Rendon-Morales, a Lecturer in Electrical and Electronic Engineering at the University of Sussex, said: "Currently expectant mothers with health concerns about their babies have to go through the stress of going to hospital to check on the heartbeat of their child. With this new technology, they will be able to do this from the comfort of their own home, which will be much better for the welfare of mother and baby."
The research is the first significant update in the technology used to measure babies' heart rates for 40 years and moves away from the existing use of silver chloride electrodes.
Instead, the University of Sussex has developed an electrometer-based amplifier prototype using Electric Potential Sensing (EPS) technology, which allows for in utero fetal electrocardiogram monitoring by just placing the device on top of the skin of the pregnant mother's abdomen in a non-invasive way.
Although there are some home-based fetal electrocardiograms available commercially, they are considered not suitable for daily or medical usage because of concerns around their accuracy and portability.
Dr Rodrigo Aviles-Espinosa, a research fellow at the University of Sussex and co-author of the study said: "This technology is a step forward for home-based medical devices, benefiting not only health service providers though resource optimization, but also expectant mothers who are experiencing a very exciting, but sometimes stressful, moment in their lives.


"This technology will give peace of mind in providing answers very quickly and ultimately ensuring the baby's wellbeing."
The technology developed at the University of Sussex is capable of recording information required to calculate fetal heart rate values and variability with high accuracy.
This can be used to clinically assess congenital cardiac diseases such as arrhythmia and to monitor processes associated with body auto regulation such as blood pressure and heart vascular tone.
The electrocardiogram can isolate the baby's heartbeat from the mother's with pinpoint accuracy, providing a simple reading without the need for any additional processing.
Devices currently in use require complex signal-conditioning algorithms to separate the maternal and fetal cardiac waveforms.
The new detector also removes the need for a special gel to be applied to the skin. This is necessary when using silver chloride electrodes, in order to establish a reading, but the process can produce inaccurate readings.
Dr Rendon-Morales said: "Although the ultrasound procedure is described as being non-invasive, having gel rubbed on your skin and then an electrode pressed against your womb is invasive and can be an uncomfortable experience for mothers. With this new heart monitor, expectant mothers can get reassurance that their baby is doing fine within a few seconds, removing the unnecessary stress and worry that waiting for a hospital scan currently involves."
The new baby monitor has grown out of previous work Dr Rendon-Morales had published in 2015 in which she used highly sensitive sensors to map the electrical activity of the developing heart in the embryos of zebrafish, which are 2,500 times smaller than human hearts.
The potential of the technology to be adapted for human mothers and babies was recognized by Dr Heike Rabe, a consultant neonatologist at Brighton and Sussex Medical School.
Dr Rabe said: "At the moment it is sometimes difficult to distinguish between the heartbeat of the mother and that of the baby with the current ultrasound technique. Often there is signal loss as well. With the new technique we hope to recognize much earlier if a baby should be delivered quickly if their heart rate drops and does not recover."

#WCGO-2019  #CallForAbstracts   #OrganizingComiittee

@Facebook  https://twitter.com/Thirupa41130130 @LinkedIn


Maternal-fetal medicine

Scientific Federation is conducting World Congress on Gynecology & Obstetrics (WCGO-2018)  on September 20-21, 2018 at Toronto, Canada.
WCGO-2018 is anticipating over 150-200 participants from all over the world. The official opening ceremony will take place on September 20-21 at  Holiday Inn Toronto International Airport 970 Dixon Road, Toronto, ON M9W 1J9, Canada

This year we are focusing on
Expedite the Future Endeavour’s in Gynecology and Obstetrics Care”
WCGO-2018 Scientific sessions includes Reproductive medicine, Reproductive Medicine, IVF, Family planning, Epidemiology of Gynecologic Cancers, Gynecological Oncology, Primary Peritoneal Cancer, Gynecological Endocrinology, Reproductive Cancer, Cesarean Delivery, Polycystic Ovary Syndrome,  Pregnancy etc…
There are plenary talks, oral talks and workshops on Maternal-fetal session

Maternal-fetal medicine:
Maternal–fetal medicine  is a branch of medicine that focuses on managing health concerns of the mother and fetus prior to, during, and shortly after pregnancy .
                                    
The field of maternal–fetal intervention is rapidly evolving with new technologies and innovations. This raises complex ethical and medico-legal challenges related to what constitutes innovative treatment versus human experimentation, with or without the umbrella of “medical research.” There exists a gray zone between these black and white classifications, but there are also clear guidelines that should be responsibly negotiated when making the essential transition between an innovative treatment and a validated therapy. This review attempts to define some of the current and future ethical challenges in maternal–fetal research, and to offer constructive insight into how they might be addressed.
The clinicians who developed technologies for assisting human reproduction had a double motivation. Paternalistic concern to help women experiencing difficulties with reproduction was coupled with a utilitarian ethic that assumed that such innovations would result in more benefit than harm. Current techniques donor insemination, the induction of ovulation, in-vitro fertilization, antenatal screening for fetal abnormality, antenatal diagnosis (with the option of abortion), and fetal treatment in utero were accepted because of their obvious benefits. They became routine practice long before adverse effects were quantified, and before it became apparent that the clinicians' assumptions of the benefits to women and their children had been simplistic: in-vitro fertilization has resulted in the birth of children disabled by the prematurity associated with multiple pregnancy; after normal conception, the notion of pregnancy as a natural and rewarding process has been undermined by pressures to accept antenatal diagnosis and fetal monitoring.
Discussion of ethical issues and legal regulation has followed rather than led the developments in maternal—fetal medicine. The autonomy of the woman and the moral status of the fetus are central to the debate. Western secular ethics gives priority to personal autonomy, but in matters of sex and reproduction society persists in assigning more autonomy to men than to women. Men often coerce their partners into undesired sexual activity. Unintended pregnancy is disproportionately harmful to women yet their default behaviour is expected to be acceptance both of the pregnancy and of the obligation to care for the child. Full autonomy for women means equality in sexual behaviour and complete personal authority over the fetus.
But what is the moral status of the fetus It is not ‘new life’—the intracellular biological processes of the fetus are in direct continuity with those of the women, with the man adding only his half of the chromosomal genes. The fetus acquires moral status progressively throughout pregnancy, a progress that is marked by developmental milestones such as formation of the neural tube, completion of macroscopic organogenesis, functional maturation of lungs, liver and kidneys, increasing electrical maturation of the cerebral cortex, and then birth itself. Increasing moral status is also marked by the bonding that results from the woman's growing awareness of the fetus, and which, as the pregnancy becomes increasingly obvious, extends to her partner, her family, and then everyone she meets. This bonding with the fetus is the foundation for the responsibility she feels for the welfare of the future child. Birth itself is a major moral event. By ‘giving birth’, the woman confers to her new baby status as a person. The baby, unlike the fetus, does not have an obligatory dependence on the woman, and adaptation to extra-uterine life has necessitated sudden, radical and irreversible changes in its circulation and respiration. British law supports the view that the fetus is not a person at any gestation, and recent case law has established that the consent of the woman is required for any intervention in pregnancy that is considered necessary to benefit or to reduce the risk of harm to the fetus. After birth, the baby is legally a person who, if not provided with adequate care, has special protection under the Children Act. In contrast to the fetus, the wellbeing of the child is the responsibility of both parents and of society as a whole.


Scientific Federation conducting World Congress on gynecology & Obstetrics at Toronto, Canada which will be held on September 20-21, 2018.

Theme of the conference: Expedite the Future Endeavour’s in Gynecology and Obstetrics Care
For more details about the conference: http://scientificfederation.com/gynecology-2018/
It is a two days conference will provoke plenary sessions, Keynote speeches, Poster, and Oral presentations.
Earlybird Registration on/before February 28, 2018
Standard Registration on/before May 25, 2018
On Spot Registration on September 20, 2018
All Abstracts Will be Published on the Conference Book
Abstract Submission deadline is August 30, 2018
Scientific Sessions include:-
·         Reproductive Medicine
·         IVF
·         Family planning
·         Polycystic Ovarian Syndrome
·         Epidemiology of Gynecologic Cancers
·         Gynecological Oncology
·         Primary Peritoneal Cancer
·         Quality of Life of Patients with Gynecologic Cancers
·         Reproductive Cancer
·         Socio- Psychological Aspects of Gynecological Cancers
·         Targeted Molecular Therapy for all Gynecologic Cancers
·         Cesarean Delivery
·         Polycystic Ovary Syndrome
·         Pregnancy
·         Pregnancy Diabetes
·         Obstetrics and Gynecology
·         Minimally Invasive Gynecology
·         Gynecological Diagnosis and Treatment
·         Gynecological issues
·         Advanced laparoscopic surgery
·         Post term pregnancy
·         Ultrasound in Obstetrics and Gynecology
·         Pediatric and adolescent gynecology
·         Menopausal and geriatric gynecology
·         Obstetric Nursing
·         Obstetric Fistula
·         Gynecology and Fertility
·         Gynecological Cancer
·         Reproductive Gynecology
·         Maternal-fetal medicine
Our Plenary speakers are
Ø  JoAnn E. Manson
                Harvard Medical School, USA
Ø  Horvath, Steve
               University of California, USA
Ø  Mark Kilby
               University of Birmingham, UK
Ø  Panos Zavos
     University of Minnesota, USA
Ø  Luca Gianaroli
Chairmen of the Board of SISME, Italy

We are planning to conduct workshop on In vitro fertilization
Did you know that there are 6.7 million women suffering from infertility today in the US alone? Yet, despite the increasing infertility rates, modern medicine has been quick to come up with solutions.

Even though studies of human embryology and developmental biology began in the 18th century, the most notable progress has occurred in just the last two to three decades.

Women having trouble conceiving can choose from a number of Assisted Reproductive Technologies (ARTs) such as: artificial insemination, in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT) and others. The IVF process is by far the most common.

There are a number of factors that can determine the outcome of the procedure. Age and fitness of the would-be mother can severely influence the IVF cycle. Though, despite being a fairly complicated process it remains relatively safe and it has lead to more than 5 million births worldwide.

If you’re considering using IVF or you want to work as an IVF technologist, learn more about this innovative technology below.

Lab-grown eggs could aid fertility treatments

                                                                        
Magnification of a lab-grown, fully matured human egg ready for fertilization.
Scientists have grown egg cells, which were removed from ovary tissue at their earliest stage of development, to the point at which they are ready to be fertilised.

Egg storage
The advance could safeguard the fertility of girls with cancer ahead of potentially harmful medical treatment, such as chemotherapy.
Immature eggs recovered from patients’ ovarian tissue could be matured in the lab and stored for later fertilization.
Conventionally, cancer patients can have a piece of ovary removed before treatment, but reimplanting this tissue can risk reintroducing cancer.
The study has also given insight into how human eggs develop at various stages, which could aid research into other infertility treatments and regenerative medicine.
Developing cells
Scientists and medical experts worked together to develop suitable substances in which eggs could be grown – known as culture mediums – to support each stage of cell development.
Their findings, using tissue donated by women who were undergoing routine surgery, build on 30 years of research.
In previous studies, scientists had developed mouse eggs to produce live offspring, and had matured human eggs from a relatively late stage of development.
The latest study is the first time a human egg has been developed in the lab from its earliest stage to full maturity.

About the Venue
Holiday Inn Toronto International Airport
970 Dixon Road, Toronto, ON M9W 1J9, Canada




Best regards,
Organizing Committee members of the conference
Hans-Peter Steiner
Karl-Franzens-University of Graz,
Austria
Seang Lin Tan
McGill University, Canada
EmadDarwish
Alexandria University, Egypt
Gamal Sayed
The University of Dundee, United
Kingdom
Stergios Doumouchtsis
Epsom & St Helier University Hospitals

Cesarean Delivery


This comprehensive analysis systematically reviewed 60 authoritative studies related to postpartum VTE outcomes. Investigators found that CS carries a fourfold greater VTE risk than VD. "We found that CS is an important independent risk factor for the development of VTE in the postpartum period and that approximately three VTE will occur for everything 1,000 CS performed, with greater risks for nonscheduled emergency CS," said lead investigator Marc Blondon, MD, Division of Angiology and Hemostasis, Geneva University Hospitals, Geneva Switzerland. These risks were largely independent of other factors like maternal age and body mass index.
Pregnant women become more susceptible to VTE due to a variety of factors, including venous stasis and trauma associated to delivery. Also, hemostatic changes drive increases in some coagulation factors, while decreasing bleeding inhibitors, but for some reason these changes seem to be worse for women who deliver via CS. "In the postpartum period specifically, women following CS exhibit greater activation of coagulation than women following VD, as reflected by greater D-dimer levels," explained Dr. Blondon. D-dimer levels indicate that blood clots may be forming or breaking down in the body. "This outcome may be a result of the conditions leading to the CS or to the procedure itself, similar to the increased VTE risk following non-obstetric surgery. Furthermore, physical activity is reduced following CS compared with following VD, with delayed recovery of mobility occurring in the first two days following delivery."
As with many non-obstetric surgical procedures, thromboprophylaxis, or preventive measures taken to try and stop VTE before it happens, is commonly employed to try and minimize risk; however, researchers found little evidence on the use of thromboprophylaxis after CS.
Key words: Cesarean Delivery, pregnancy.

Women health


"Women with only a small weight gain each year (1.5 to 2.5 per cent of body weight) doubled their risk of gestational diabetes,"
"Surprisingly, even women who were underweight or in the normal BMI range had an increased risk of gestational diabetes when they gained weight -- even if they remained within the healthy weight category.
"Women with small weight gains within the healthy BMI range doubled their risk of gestational diabetes compared to women whose weight remained stable."
Obesity is a known risk factor for gestational diabetes, which can lead to large babies, birth complications and long-term health risks for mothers and children.
Researchers set out to see what impact weight change had in the years leading up to pregnancy.
They tracked more than 3000 participants from the Women's Health Australia study (also known as the Australian Longitudinal Study on Women's Health).
The women, aged between 18 and 23 when they joined the study in 1996, have answered regular surveys on their weight, physical activity, lifestyle, health issues, and pregnancies ever since.
"It's important for women and their clinicians to be aware that, even in the healthy BMI range, gaining a kilogram or two a year can be a health risk,"
Key words: Diabetes, pregnancy, women health


Stem cells


Stem cells have the ability to develop into other cell types, and existing stem cell lines are already extremely useful for research into development, disease and treatments. However, the two currently available types of stem cell lines -- Embryonic Stem cells (ES) and induced Pluripotent Stem cells (iPS) -- have certain limitations. It is not currently possible for them to form every type of cell since they are already excluded from developing certain cell lineages.
To discover new stem cells for use in research and regenerative medicine, the researchers created a way of culturing cells from the earliest stage of development, when the fertilised egg has only divided into 4 or 8 cells that are still considered to retain some totipotency -- the ability to produce all cell types. Their hypothesis was that these cells should be less programmed than ES cells, which are taken from the around-100-cell stage of development -- called a blastocyst. They grew these early cells in a special growth condition that inhibited key development signals and pathways.
The scientists discovered that their new cultured cells kept the desired development characteristics of the earliest cells and named them Expanded Potential Stem Cells (EPSCs). Importantly, they were also able to reprogramme mouse ES cells and iPS cells in the new condition and create EPSCs from these cells, turning back the development clock to the very earliest cell type.
Key words: stem cells, egg, fertilization